Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-110 + erlotinib
- Development stage
- Discontinued
- Lead developer
- Tivic Health Systems
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Intradermal, Oral
01
Overview
**HS-110 + erlotinib** is an investigational combination therapy comprising HS-110 (a cell-based therapeutic cancer vaccine) administered with erlotinib (a small-molecule tyrosine kinase inhibitor). HS-110 is an allogeneic, off-the-shelf tumor cell vaccine designed to induce T-cell mediated antitumor immunity, primarily targeting lung cancer antigens. Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), acting by inhibiting EGFR-mediated signaling that drives tumor cell proliferation. The combination aims to enhance immune response while blocking EGFR-driven tumor cell survival pathways. Investigational trials have evaluated safety, tolerability, and immunologic activity of this regimen in advanced NSCLC[1].
- Other names
- HS-110 plus erlotinibHS110 plus erlotinibHS 110 plus erlotinibHS-110 and erlotinibHS110 and erlotinibHS 110 and erlotinib
02
Targets
JAK2 V617F (Janus kinase 2 V617F mutant)UGT1A1 (UDP-glucuronosyltransferase 1A1)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on HS-110 + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-110 + erlotinib.